Recap - A happy (belated) Thanksgiving to you and yours! Last week we wrote briefly about the current state of the markets, from a technical perspective. Conclusion: a short-term pull-back … Continue Reading
Read NowRecap - The markets have rebounded precipitously from lows this October, with both the S&P 500 and iShares NASDAQ Biotechnology Index (IBB) making new all-time highs in the … Continue Reading
Read NowInsights - Celldex Therapeutics (CLDX) has climbed 100% from all-time lows this summer – 40% in the last week – on encouraging and arguably groundbreaking results from a phase II … Continue Reading
Read NowInsights - Pfizer (PFE) put up $850 million to partner with Merck KGaA on a number of immuno-oncology drugs.
Read NowRecap - As expected, Trillium Therapeutics (SCTPF)(TR.TO) announced this week an upcoming reverse-split, NASDAQ uplisting, and reiterated the timeline for bringing its SIRPaFc antibody-like fusion proteins into the clinic … Continue Reading
Read NowResearch - Last week, preliminary data for bluebird bio (BLUE)’s Lentiglobin were released as part of the abstract dump for ASH in December (we wrote at length about this, here). Bluebird … Continue Reading
Read NowInsights - Dendreon (DNDN) has filed for bankruptcy protection and reached agreement with a majority of its debtholders to convert to equity in the company.
Read Now
